What is the prognosis of translocation-associated renal cell carcinomas (RCCs)?

Updated: May 17, 2017
  • Author: Angela J Wu, MD; Chief Editor: Liang Cheng, MD  more...
  • Print


There is controversy regarding the prognosis of patients with Xp11.2 renal cell carcinoma (RCC). Although some early series and smaller series reported a relatively indolent course, later series reported a relatively poor prognosis for these patients. [1, 3, 6, 7, 8, 13, 14] In our experience, with a median follow-up time of 2.8 years, approximately one half of patients ultimately die of disease. [3]

There is some evidence that although patients with these tumors are likely to present with tumors at higher stages, the presence of lymph node metastases alone in the absence of hematogenous spread does not necessarily portend a worse prognosis, at least in the short term. Patients who develop hematogenous metastases, however, seem to have a dismal prognosis. [5] Complicating these data is the fact that there have been several case reports of recurrences of Xp11.2 translocation-associated RCC occurring as long as 20-30 years after initial resection. [26, 27]

Although there is limited follow-up for the reported cases of t(6;11) translocation-associated RCC, in the majority of cases, there has been no evidence of disease following resection. At least 2 patients with t(6;11) RCC, however, died with multiple metastases relatively soon after resection. [1, 2]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!